Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage TherapeuticsPRNewsWire • 03/07/24
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million FinancingGlobeNewsWire • 03/06/24
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic FibrosisGlobeNewsWire • 01/04/24
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023GlobeNewsWire • 11/30/23
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic FibrosisGlobeNewsWire • 11/29/23
BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any DaySeeking Alpha • 11/23/23
BiomX Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/23
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis ConferenceGlobeNewsWire • 10/27/23
BiomX Announces the Appointment of Edward L. Williams to its Board of DirectorsGlobeNewsWire • 10/18/23
BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic FibrosisGlobeNewsWire • 10/04/23
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023GlobeNewsWire • 09/07/23
BiomX Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/23
BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023GlobeNewsWire • 08/02/23
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of BiomX Inc. (PHGE.WS)Business Wire • 06/02/23
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis ConferGlobeNewsWire • 05/31/23
BiomX Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/23
BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023GlobeNewsWire • 05/08/23